Values First Advisors Inc. Boosts Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Values First Advisors Inc. boosted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 11.6% in the fourth quarter, Holdings Channel reports. The fund owned 59,205 shares of the company’s stock after purchasing an additional 6,140 shares during the quarter. Values First Advisors Inc.’s holdings in Recursion Pharmaceuticals were worth $584,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its position in Recursion Pharmaceuticals by 116.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after buying an additional 2,817 shares in the last quarter. Amundi grew its position in shares of Recursion Pharmaceuticals by 69.6% during the fourth quarter. Amundi now owns 7,189 shares of the company’s stock worth $57,000 after purchasing an additional 2,949 shares in the last quarter. Baldwin Brothers LLC MA grew its position in shares of Recursion Pharmaceuticals by 33.3% during the third quarter. Baldwin Brothers LLC MA now owns 7,336 shares of the company’s stock worth $56,000 after purchasing an additional 1,834 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Recursion Pharmaceuticals by 25.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after purchasing an additional 2,050 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter worth about $79,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 20,054 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $10.58, for a total transaction of $212,171.32. Following the transaction, the director now directly owns 7,324,364 shares in the company, valued at approximately $77,491,771.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 20,054 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $10.58, for a total transaction of $212,171.32. Following the transaction, the director now directly owns 7,324,364 shares in the company, valued at approximately $77,491,771.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the transaction, the chief operating officer now owns 414,548 shares in the company, valued at $4,290,571.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 353,107 shares of company stock worth $3,856,834. 19.96% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

RXRX has been the subject of several research analyst reports. KeyCorp increased their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC increased their price target on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, TD Cowen assumed coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a “market perform” rating for the company. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX traded down $0.20 during trading on Thursday, hitting $9.97. The company had a trading volume of 5,181,308 shares, compared to its average volume of 7,178,251. The company has a fifty day simple moving average of $11.16 and a two-hundred day simple moving average of $9.04. Recursion Pharmaceuticals, Inc. has a one year low of $4.54 and a one year high of $16.75. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -6.43 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.